Health and Healthcare
Credit Suisse Identifies 5 Stocks to Buy Winning From Your Pet's Health
Published:
Last Updated:
Credit Suisse made a point to highlight a few animal health companies that stand to outperform the markets in 2016 and even beyond. Most investors might not consider investing because this can be somewhat of a niche industry, but some of the best value can be found in these types of industries.
24/7 Wall St. has put together a montage of these companies and their respective ratings. We have also included the consensus price target, a recent trading history and the 52-week trading range.
Zoetis Inc. (NYSE: ZTS) coverage was initiated with an Outperform rating and a $58 price target. This is Credit Suisse’s top-rated animal health company. As the global leader in therapeutics for livestock and companion animals, Zoetis is highly levered to rebounding industry fundamentals, and earnings growth should accelerate over an improving cost and capital structure. The firm’s focus is on underappreciated efficiency initiatives that should drive over 900 basis points operating margin expansion by 2017, a considerable feat for a company of its size that ensures double-digit earnings growth in 2017 and beyond. Shares of Zoetis were trading at $41.37 on Thursday, with a consensus analyst price target of $51.82 and a 52-week trading range of $37.73 to $55.38.
IDEXX Laboratories Inc. (NASDAQ: IDXX) was initiated with an Outperform rating and an $80 price target. Following a transition year, IDEXX is well-positioned in an improving animal health market with primary drivers in innovation, an expanding installed base and broader geographic expansion as its direct distribution strategy matures, which should fuel the stock by over 10%. Shares of IDEXX were trading at $71.68, with a consensus price target of $67.17 and a 52-week range of $61.37 to $82.24.
24/7 Wall St.Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Editors' Picks
